Eliem Therapeutics, Inc.
ELYM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $279 | $278 | $277 | $276 |
| - Cash | $26 | $23 | $29 | $87 |
| + Debt | $1 | $1 | $0 | $1 |
| Enterprise Value | $254 | $256 | $249 | $190 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13 | -$11 | -$23 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$9 | -$21 | -$8 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.19 | -0.13 | -0.31 | 0.47 |
| % Growth | -46.2% | 58.1% | -166% | – |
| Operating Cash Flow | -$12 | -$11 | -$15 | -$12 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$12 | -$11 | -$15 | -$12 |